Trial Profile
A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent Asthma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2012
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- 23 Oct 2012 Planned number of patients changed from 320 to 340.
- 22 Jun 2011 New trial record